| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Urology,* Pathology, and Pharmacology, and the Division of Medical Oncology, Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Previously, we and others showed that broad spectrum pharmaceutical inhibition of matrix metalloproteinase (MMP) activity reduces intraosseous tumor burden and bone degradation in animal models of bone metastasis. Herein, we used specific assays to measure net enzymatic activities of individual MMPs during colonization of bone by prostate cancer cells. PC3 cells were injected into the marrow of human fetal femurs previously implanted in SCID mice. Net MMP-9 activity in bone tissues peaked 2 weeks after injection, coinciding with a wave of osteoclast recruitment. In contrast, MMP-2 and MT1-MMP activity did not change. In vitro, co-culture of PC3 cells with bone tissue led to activation of pro-MMP-9 and increases in secreted net MMP-9 activity. Activation of pro-MMP-9 was prevented by metalloprotease inhibitors but not by inhibitors of other classes of proteases. Ribozyme suppression of MMP-9 expression in PC3 cells did not affect pro-MMP-9 activation or net MMP-9 activity and did not affect the phenotype of bone tumors. siRNA targeting of MMP-9 expression in preosteoclasts in vitro demonstrated that tumor-induced preosteoclast motility was dependent on MMP-9 expression. These data suggest that osteoclast-derived MMP-9 may represent a potential therapeutic target in bone metastasis and provide a rationale for the development of MMP-9-specific inhibitors.
This article has been cited by other articles:
 |
|
 |
|
  S. R. Chinni, H. Yamamoto, Z. Dong, A. Sabbota, R. D. Bonfil, and M. L. Cher CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone Mol. Cancer Res., March 1, 2008; 6(3): 446 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Nair, H. Avila, X. Ma, Z. Wang, M. Lennartz, B. G. Darnay, D. D. Boyd, and C. Yan A Novel High-Throughput Screening System Identifies a Small Molecule Repressive for Matrix Metalloproteinase-9 Expression Mol. Pharmacol., March 1, 2008; 73(3): 919 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Wallace, R. L. Prueitt, M. Yi, T. M. Howe, J. W. Gillespie, H. G. Yfantis, R. M. Stephens, N. E. Caporaso, C. A. Loffredo, and S. Ambs Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men Cancer Res., February 1, 2008; 68(3): 927 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, S. Banerjee, D. Kong, Y. Li, and F. H. Sarkar Down-regulation of Forkhead Box M1 Transcription Factor Leads to the Inhibition of Invasion and Angiogenesis of Pancreatic Cancer Cells Cancer Res., September 1, 2007; 67(17): 8293 - 8300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Bonfil, Z. Dong, J. C. Trindade Filho, A. Sabbota, P. Osenkowski, S. Nabha, H. Yamamoto, S. R. Chinni, H. Zhao, S. Mobashery, et al. Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase: A Pivotal Role in Bone Response and Intraosseous Tumor Growth Am. J. Pathol., June 1, 2007; 170(6): 2100 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moore, X.-D. Shen, F. Gao, R. W. Busuttil, and A. J. Coito Fibronectin-{alpha}4{beta}1 Integrin Interactions Regulate Metalloproteinase-9 Expression in Steatotic Liver Ischemia and Reperfusion Injury Am. J. Pathol., February 1, 2007; 170(2): 567 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Rahman, F. H. Sarkar, S. Banerjee, Z. Wang, D. J. Liao, X. Hong, and N. H. Sarkar Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol. Cancer Ther., November 1, 2006; 5(11): 2747 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, R. Sengupta, S. Banerjee, Y. Li, Y. Zhang, K.M. W. Rahman, A. Aboukameel, R. Mohammad, A. P.N. Majumdar, J. L. Abbruzzese, et al. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res., August 1, 2006; 66(15): 7653 - 7660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, O. Kucuk, M. Hussain, J. Abrams, M. L. Cher, and F. H. Sarkar Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer. Cancer Res., May 1, 2006; 66(9): 4816 - 4825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Cher, D. A. Towler, S. Rafii, D. Rowley, H. J. Donahue, E. Keller, M. Herlyn, E. A. Cho, and L. W.K. Chung Cancer Interaction with the Bone Microenvironment: A Workshop of the National Institutes of Health Tumor Microenvironment Study Section Am. J. Pathol., May 1, 2006; 168(5): 1405 - 1412. [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, S. Banerjee, Y. Li, K.M. W. Rahman, Y. Zhang, and F. H. Sarkar Down-regulation of Notch-1 Inhibits Invasion by Inactivation of Nuclear Factor-{kappa}B, Vascular Endothelial Growth Factor, and Matrix Metalloproteinase-9 in Pancreatic Cancer Cells. Cancer Res., March 1, 2006; 66(5): 2778 - 2784. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
